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Abstract
Background: Several studies in the past have investigated the expression of micro RNAs (miRNAs) in saliva as
potential biomarkers. Since miRNAs associated with extracellular vesicles (EVs) are known to be protected from
enzymatic degradation, we evaluated whether salivary EVs from patients with oral squamous cell carcinoma (OSCC)
were enriched with specific subsets of miRNAs.
Methods: OSCC patients and controls were matched with regards to age, gender and risk factors. Total RNA was
extracted from salivary EVs and the differential expression of miRNAs was evaluated by qRT-PCR array and qRT-PCR.
The discrimination power of up-regulated miRNAs as biomarkers in OSCC patients versus controls was evaluated by
the Receiver Operating Characteristic (ROC) curves.
Results: A preliminary qRT-PCR array was performed on samples from 5 OSCC patients and 5 healthy controls
whereby a subset of miRNAs were identified that were differentially expressed. On the basis of these results, a
cohort of additional 16 patients and 6 controls were analyzed to further confirm the miRNAs that were up-
regulated or selectively expressed in the previous pilot study. The following miRNAs: miR-302b-3p and miR-517b-3p
were expressed only in EVs from OSCC patients and miR-512-3p and miR-412-3p were up-regulated in salivary EVs
from OSCC patients compared to controls with the ROC curve showing a good discrimination power for OSCC
diagnosis. The Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway analysis suggested the possible
involvement of the miRNAs identified in pathways activated in OSCC.
Conclusions: In this work, we suggest that salivary EVs isolated by a simple charge-based precipitation technique
can be exploited as a non-invasive source of miRNAs for OSCC diagnosis. Moreover, we have identified a subset of
miRNAs selectively enriched in EVs of OSCC patients that could be potential biomarkers.
Keywords: Oral squamous cell carcinoma (OSCC), Extracellular vesicles (EVs), microRNA (miRNA), miRNA-512-3p
(miR-512), miRNA-412-3p (miR-412), miR-302b-3p (miR-302b), miR-517b-3p (miR-517b), miR-27a-3p (miR-27a), miR-494
Background
Oral squamous cell carcinoma (OSCC) is the most
frequent cancer of the head and neck [1, 2]. Despite
outstanding diagnostic and therapeutic improvements in
oncology, OSCC still holds a poor prognosis with an
estimated 5-year overall survival rate of 56% both in the
United States and Western Europe [1, 2]. Specifically, in
northern Italy, the 3-year and 5-year overall survival rate
has been estimated to be 57% and 49% [3] with the latter
decreasing dramatically when considering advanced or
metastatic cases. Although, in recent years different
biological and molecular factors have been described for
the prognosis of OSCC, none of them have had a real
impact on routine clinical care. Histopathological staging
still remains the gold standard for post-operative man-
agement and prognosis of the disease [4]. Hence, more
reliable and time saving diagnostic tools are needed.
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In OSCC, metastasis spreads predominantly via a lymph-
atic route with cervical lymph nodes (LN) as the first loca-
tion, whereas metastasis to distant sites is relatively
uncommon [5]. Efficient detection and removal of LN me-
tastasis is therefore crucial in the treatment and survival of
patients with this form of carcinoma. Therefore, great
expectations lie on the identification of specific predictive
factors that could be used clinically for the diagnosis,
prognosis and monitoring of the therapeutic response.
In the last decade, extracellular vesicles (EVs) have
gained significant attention as a conceivable source of
biomarkers. These small membrane-bound vesicles are
categorized into 3 different types: exosomes, microvesicles
or ectosomes, and apoptotic bodies [6]. EVs are secreted
under different physiological and pathophysiological
conditions into the extracellular milieu by a variety of cell
types, including tumor cells. Tumor-derived EVs have
been identified to influence the tumor environment by
promoting cancer progression, survival, invasion, and
angiogenesis [7]. However, as EVs carry biologically active
proteins and nucleic acids from the parent cells, tumor-
derived EVs could therefore act as molecular signatures of
cancer cells from which they are derived [7, 8].
MicroRNAs (miRNAs) are small non-coding RNA
molecules approximately 22 nucleotides in length, which
act as regulatory gatekeepers of coding genes. MiRNAs
are expressed in a tissue-specific manner, and changes in
their expression within a tissue can be correlated with a
disease status [9]. Furthermore, they can also modulate
gene expression by regulating mRNA translation and/or
degradation depending on complementarity between the
miRNA and the mRNA [10]. MiRNAs can be secreted
either through EVs and/or by forming protein-miRNA
complexes with molecules such as high-density lipopro-
teins and AGO2, which are part of the RISC complex.
However, miRNAs carried in EVs are more stable once
released as the encapsulation provides protection from
enzyme degradation. This therefore makes them more
promising as next-generation biomarkers for cancer
diagnosis and prognosis [8]. To date, cancer biomarkers
carried by EVs have been studied in several types of tu-
mors [9, 11–13], including head and neck cancer [14].
However, no work has been published on the expression
of miRNAs in EVs from saliva of patients with OSCC.
The aim of the present study was therefore to evaluate
whether salivary EVs of OSCC patients and healthy con-
trols express a different pattern of miRNAs and whether
the differentially expressed miRNAs could be applied as
potential biomarkers for OSCC.
Methods
Selection of patients
The enrolled subjects were attending the Oral Medicine
Section of the Department of Surgical Sciences, University
of Turin, CIR-Dental School, between January and June
2015. Patients with biopsy-proven OSCC were involved in
the study with the exclusion of patients with the following
criteria: 1) < 18 years of age, 2) pregnant or breast feeding,
3) psychiatrically or mentally unstable. Local ethical com-
mittee approval (n° 310/2015, “A.O.U. Città della Salute e
della Scienza di Torino”, Turin, Italy) was obtained and all
patients provided written informed consent. Demographic
information, age at the time of diagnosis and gender,
smoking, tumor site, and TNM classification [15] were
recorded at baseline (Table 1 and Additional file 1:
Table S1). Healthy subjects presenting no clinically
detectable oral lesions matched for age, gender, and risk
factors were recruited as controls (Table 1).
Saliva collection
As previously reported [16], all subjects were asked to
refrain from: eating, drinking, or oral hygiene for at least
one hour prior to collection (usually between 9 and
11 a.m.); they then rinsed their mouths with water
and then waited for at least 5 min before spitting into
a 50 ml Falcon tube. Participants were instructed not
to cough or forcefully expectorate in order to collect un-
stimulated saliva samples.
HPV-16 in situ hybridization
In situ hybridization (ISH) for HPV was performed on
hematoxylin and eosin sections using the Bond TM
Ready-to-Use ISH HPV Probe (Leica Biosystems,
Newcastle, UK) which targets the following subtypes: 16,
18, 31, 33, and 51. ISH was carried out following the
manufacturer’s instructions on the automated Leica
BOND system (BOND-MAX, Leica Biosystems).
EV isolation
The sample of saliva from patients with OSCC and
healthy controls was diluted 1:1 with PBS (phosphate
buffered saline) and centrifuged at 3000 g for 15 min at
room temperature to remove cells, debris and bacteria.
The supernatant was filtered with 0.2 μm filters and
Table 1 Characteristics of OSCC patients and controls enrolled
in the study
Characteristics OSCC patients Controls P value
Number 21 11
Age 65.75 [61; 73] 61.64 [61.5; 67.5] 0.381
Range 38–78 39–75
Gender (male/female) 12 (57%)/9 (43%) 6 (55%)/5 (45%)
Smokers 6 (28%) 3 (27%)
For each group, the table indicates the total number of subjects, the mean
age of each group and quartiles [Q1; Q3], the minimum and maximum age of
enrolled subjects, number and percentage of male and female and of
smokers. The differences in ages between the two groups were not
statistically significant (Student’s t test)
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transferred to a sterile tube after which, a precipitation
solution (65 μL per 250 μL of saliva) was added and the
mixture incubated at 4 °C overnight. The following day,
samples were centrifuged at 3000 g for 30 min to pre-
cipitate EVs. The resulting supernatant was removed and
samples re-centrifuged at 1500 g for 5 min to remove
any remaining supernatant [17]. The pellet was resus-
pended in either: 100 μL of PBS for NanoSight analysis,
or 100 μl of RIPA lysis buffer (Sigma Aldrich, Milan, IT)
for protein extraction, or 600 μL of Lysis/Binding
Buffer (mirVana Isolation Kit, Thermo Fisher Scientific,
Waltham, MA, USA) and stored at − 80 °C for subse-
quent RNA extraction.
EV characterization
The EV samples isolated from saliva were diluted 1:200
in physiologic solution and analyzed by NanoSight LM-
10 (Malvern Instruments Ltd., Malvern, UK). The
average number and size of EVs were measured by
Nanoparticle Tracking Analysis (NTA) software (Malvern
Instruments Ltd). Transmission electron microscopy
(TEM) of negatively stained EVs (NanoVan, Nanoprobes,
Yaphank, NK, USA) was also performed as described
previously [17] and the images were obtained using the
Joel JEM 1010 electron microscope (Jeol, Tokyo, Japan).
Western blot analysis
Protein concentration in EV samples was measured by
Bradford assay. Protein samples were loaded on poly-
acrylamide gel at the concentration of 30 μg/well and
separated by SDS/PAGE, using 4–15% precast gel
(Mini-PROTEAN® Precast Gels, Bio-Rad, Hercules,
CA, USA). Proteins were transferred on nitrocellulose
membranes by liquid electrophoresis. Membranes
were immunoblotted by polyclonal antibodies anti-
CD9, CD63, TSG101, and Alix (Santa Cruz Biotech-
nologies, Dalls, TX, USA). Protein-bands were de-
tected by chemiluminescent Clarity™ ECL Western
Blotting Substrate (Bio-Rad) and analyzed by Chemi-
Doc™ XRS + System (Bio-Rad).
RNA extraction and quantification
miRNAs were extracted from purified EVs by mirVana
Isolation Kit (Thermo Fisher Scientific), according to the
manufacturer’s instruction. RNA concentration was mea-
sured by Nanodrop ND-1000 (Thermo Fisher Scientific),
and the ratio 260/280 and 260/230 showed no contamina-
tions. RNA integrity was assessed by a Bioanalyzer
(Agilent, Santa Clara, CA) using the RNA 6000 Pico Kit
(Agilent).
miRNA expression analysis by qRT-PCR array
To select differentially expressed miRNAs, qRT-PCR
array analysis was performed on EVs isolated from five
patients with OSCC and five healthy controls. The con-
centration of selected RNA samples was up to 20 ng/μl
and 50 ng of total RNA were retro-transcribed to cDNA
with TaqMan® MicroRNA Reverse Transcription Kit
(Thermo Fisher Scientific). cDNA was pre-amplified
with Megaplex™ RT Primers, Human Pool Set v3.0 and
TaqMan® PreAmp Master Mix (Thermo Fisher Scientific)
using a Veriti Thermal Cycler (Thermo Fisher Scientific).
The expression profile of a panel of 754 human
microRNAs was evaluated by a TaqMan® Array Human
MicroRNA Card Set v3.0 (Thermo Fisher Scientific) using
the real-time thermal cycler 7900HT (Thermo Fisher
Scientific).
qRT-PCR
On the basis of results obtained from the array, we
studied miRNAs up-regulated or selectively expressed by
patients in a cohort of additional 16 OSCC patients and
6 controls. 500 ng of total RNA was retro-transcribed to
cDNA with miScript II RT Kit (Qiagen, Hilden, D)
and evaluated for the expression of five miRNAs up-
regulated in patients compared to healthy controls
(miR-412-3p, miR-489-3p, miR-512-3p, miR-597-5p,
and miR-603). Furthermore, eight miRNAs exclusively
expressed only in OSCC patients (miR-27a-3p, miR-
302b-3p, miR-337-5p, miR-373-3p, miR-494-3p, miR-
517b, and miR-520d-3p, miR-645) were also evaluated.
Each sample was run in triplicate and each miRNA-
specific primer was run in a separate reaction. SnoRNA
RNU6B and miR-191 were used as endogenous control as
previously described [18–20] due to their stable expres-
sion in saliva samples which was also confirmed in the
current study by qRT-PCR in tested salivary EV samples.
The qRT-PCR reaction mix was composed of 2 ng of
cDNA, 100 nM miScript Universal Primer (Qiagen),
100 nM miRNA-specific primer (Eurofins Genomics,
Ebersberg, D), 5 μl QuantiTect SYBR Green PCR Master
Mix (Qiagen), and nuclease free water (Qiagen) to reach
a final reaction volume of 10 μl. The Real-Time Thermal
Cycler Quant Studio 12 k (Thermo Fisher Scientific) was
used for analysis.
Enrichment analysis
Enrichment analysis for biological pathways was per-
formed for miRNAs that were found to be up-regulated
(p < 0.09) or only expressed by OSCC patients. Kyoto
Encyclopedia of Gene and Genomes (KEGG) pathway
analysis was performed through the DIANA-mirPath v.
3.0 [21] online software and miRNA targets were
searched on microT-CDS [22]. Results were merged by a
“pathway-union” criterion. The p value was calculated
by DIANA software online with: False Discovery Rate
(FDR) correction, p value threshold at 0.05 and MicroT
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threshold at 0.8. Fisher’s exact test was used as the
statistical method for the enrichment analysis.
Discrimination power analysis
The discrimination power of the up-regulated miRNAs
as biomarkers for OSCC diagnosis was evaluated by the
Receiver Operating Characteristic (ROC) curves [23].
The ROC curves were constructed using the relative
quantification (RQ) of the expression levels of controls
and OSCC patients by the demo version of GraphPad
Prism 6.01 software. Sensitivity, specificity, area under
curve (AUC) and p value were calculated by the soft-
ware. The optimal threshold value was decided using
Youden’s index (sensitivity + specificity-1) [24].
Statistical analysis
For array data analysis, SDS Software v.2.3 (Thermo
Fisher Scientific) was used to calculate Raw Ct values,
with an automatic baseline and threshold. Expression-
Suite Software 1.1 (Thermo Fisher Scientific) was used
to calculate RQ (2-ΔΔCt) values. Data were normalized
using global normalization, an algorithm that finds the
assays common to every sample and then uses the median
Ct of those assays as the normalization factor, on a per
sample basis [25]. Ct values > 35 or with Amp score < 0.7
were excluded from the analysis. To identify candidate
miRNAs differentially expressed between patients and
controls, we selected miRNAs with low p values (p ≤ 0.05).
P values were calculated by the ExpressionSuite software
using Student’s t-test for sample group comparisons, with-
out multiple test correction. Further to this, we screened
the group for miRNAs expressed in every sample and with
low variability among the same group.
For qRT-PCR data analysis, Excel software (Microsoft
Office 365 ProPlus) was used to calculate ΔCt, −ΔΔCt,
and RQ for patients and controls. Statistical analysis was
performed on RQ values through the demo version of
GraphPad Prism 6.01 software using an unpaired non-
parametric two-sided Mann-Whitney test. Confidence
level was set at 95% (p value ≤0.05).
Results
Patient characterization
A total of 21 patients with OSCC (12 men and 9
women) were analyzed (Table 1). The TNM staging sys-
tem identified the following lesion categories: T1 (n = 7),
T2 (n = 8), T3 (n = 3), T4 (n = 3); according to the hist-
ology, of biopsy specimens, three patients were identified
as well differentiated, twelve as moderately differentiated
and six as poorly differentiated. The lateral border of the
tongue was the most commonly affected site (24%),
followed by the floor of the mouth and gingiva (19% re-
spectively), the palate (14%), the pelvis (9.5%) and lastly
other sites (19%) (Additional file 1: Table S1). Five, out
of 21 patients, were positive for HPV (23.8%). A total of
11 controls (seven men and four women) were also ana-
lyzed. The subjects did not show oral lesions, infections,
or tumor history. Controls and OSCC patients were
matched based on gender, age and risk factor, as shown
in Table 1.
EV characterization
According to NanoSight results, EVs isolated from saliva
samples through charge-based precipitation appeared as
a heterogeneous population with a size ranging from
100 to 300 nm (Fig. 1a). TEM analysis confirmed the
characteristic shape, aspects, and dimensions of EVs
(Fig. 1b). Furthermore, we observed that the size and
concentration of salivary EVs from OSCC patients were
slightly increased compared to healthy controls, how-
ever, the differences were not statistically significant.
Western Blot analysis demonstrated the expression of
the typical exosome markers: CD63, CD9, TSG 101, and
Alix (Fig. 1c). Additionally, Western blot analysis per-
formed in duplicate on samples from 10 OSCC patients
and 8 controls was also positive for the exosome
markers: CD63 and TSG 101 marker, confirming the re-
producibility of the isolation method (Additional file 2:
Figure S1). The expression of the exosome markers was
similar for both OSCC patients and controls. According
to Bioanalyzer results, RNA cargo is mainly constituted of
RNAs ranging from 20 to 200 nucleotides, whereas the
ribosomal RNAs 18 s and 28 s were absent (Figure 1d).
No differences were observed between RNA profiles of
OSCC patients and controls (Additional file 3: Figure S2).
miRNA expression analysis by qRT-PCR array
On analyzing the expression of miRNAs in salivary EVs,
we identified five miRNAs to be up-regulated (miR-412-
3p, miR-489-3p, miR-512-3p, miR-597-5p, and miR-603),
and six miRNAs down-regulated (miR-193b-3p, miR-30e-
3p, miR-376c-3p, miR-484, miR-720, and miR-93-3p) in
tumor EVs compared to controls (Table 2). Moreover,
eight miRNAs were exclusively detected in EVs from
OSCC patients, while 14 miRNAs were specific only to
EVs from controls (Table 3). The complete qRT-PCR array
results are shown in Additional file 4: Table S2, reporting
all miRNAs expressed in EVs of both groups of patients.
qRT-PCR expression analysis
After an initial screening by qRT-PCR array, we selected
11 miRNAs for subsequent analysis. We chose the five
miRNAs up-regulated in OSCC patients (miR-412-3p,
miR-489-3p, miR-512-3p, miR-597-5p, and miR-603)
and eight miRNAs expressed only by OSCC patients
(miR-27a-3p, miR-302b-3p, miR-337-5p, miR-373-3p,
miR-494-3p, miR-517b, and miR-520d-3p, miR-645).
The analysis of the up-regulated miRNAs showed a
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Fig. 1 (See legend on next page.)
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significant up-regulation of miR-412-3p and miR-512-3p
in OSCC patients with respect to controls (Fig. 2a). The
qRT-PCR analysis of miRNAs detected only in OSCC
patients through qRT-PCR array showed that miR-27a-
3p, miR-337-5p, miR-373-3p, miR-494-3p, and miR-
520d-3p were overexpressed in patients however still
present in controls (Fig. 2b). MiR-27a-3p, miR-373-3p
and miR-494-3p showed a p value lower than 0.1, indi-
cating a conserved but not statistically significant trend
of up-regulation in OSCC patients (Fig. 2b). MiR-302b-
3p and miR-517b-3p were confirmed to be expressed
only in patients (data not shown), while miR-645 expres-
sion level was comparable to controls (data not shown).
Discrimination power of miRNAs as OSCC biomarkers
ROC curves were constructed to evaluate the discrimin-
ation power of the two up-regulated miRNAs as poten-
tial biomarkers for OSCC diagnosis. For each miRNA,
the ROC curves express the sensitivity (true positive
rate) versus 1-specificity (false positive rate) at various
cut-off values, the AUC, indicating the discrimination
power of the biomarker, and the p value (Fig. 2c, d). The
optimal threshold value was set as the maximum You-
den’s index (sensitivity + specificity-1) represented as a
black circle. MiR-512-3p (Fig. 2c) and miR-412-3p (Fig.
2d) showed high sensitivity and specificity, with high
AUC values of 0.847 and 0.871 respectively, and p values
lower than 0.02.
KEGG pathway enrichment analysis
The four miRNAs (miR-512-3p, miR-412-3p, miR-27a-
3p, and miR-494-3p) confirmed to be up-regulated and
the two miRNAs (miR-302b-3p and miR-517b-3p)
confirmed to be expressed only in OSCC patients by
qRT-PCR were selected for KEGG pathway enrichment
analysis. Eight pathways were found to be significantly
enriched for at least two of the tested miRNAs (Fig. 3a).
Furthermore, Fig. 3b shows the number of predicted tar-
get genes involved in each pathway and Fig. 3c shows,
(See figure on previous page.)
Fig. 1 Characterization of salivary EVs. (a) Representative NanoSight image of isolated EVs showing particle size (nm)/concentration (10^8
particles/ml) of a representative control (left) and a representative OSCC patient (right). (b) Representative transmission electron microscopy
image of purified EVs negatively stained with NanoVan (JEOL Jem-1010 electron microscope, black line = 200 nm) of a control (left) and a patient
(right). (c) Representative western blots confirming the expression of the exosome markers: CD63, CD9, Tsg101, and Alix, on salivary EVs from a
control (left) and a OSCC patient (right). (d) Representative profiles of RNA isolated from EVs of a healthy control (left) and a patient (right).
The graphs show fluorescence intensity [FU]/nucleotide length [nt] and were obtained through bioanalyzer analysis. Four experiments were
performed with similar results
Table 2 miRNAs differentially expressed in salivary EVs of
patients with OSCC compared to healthy controls
miRNA RQ RQ Min RQ Max P value
UP miR-412-3p 9.404 5.855 15.104 0.007
miR-489-3p 35.07 17.47 70.41 0.020
miR-512-3p 5.13 2.05 12.85 0.031
miR-597-5p 3.62 1.83 7.14 0.026
miR-603 2.36 1.30 4.28 0.042
DOWN miR-193b-3p 0.26 0.05 1.27 0.042
miR-30e-3p 0.21 0.07 0.65 0.010
miR-376c-3p 0.17 0.08 0.32 0.035
miR-484 0.44 0.23 0.85 0.048
miR-720 0.29 0.09 0.96 0.017
miR-93-3p 0.39 0.15 1.05 0.044
MiRNAs were considered up-regulated (UP) or down-regulated (DOWN) for
p value < 0.05 and similar expression levels in each sample. Relative
quantification (RQ) = 2-ΔΔCt
Table 3 miRNAs exclusively expressed in salivary EVs of the
OSCC patients or the controls
miRNA Ct mean St dev
Only patients miR-27a-3p 29.5 1.33
miR-302b-3p 33.9 0.34
miR-337-5p 30.0 1.32
miR-373-3p 30.9 0.40
miR-494-3p 33.5 1.24
miR-517b 32.2 1.57
miR-520d-3p 31.2 1.42
miR-645 34.2 0.40
Only controls miR-126-5p 32.6 1.86
miR-127-3p 32.1 1.39
miR-1276 31.4 0.95
miR-1289 33.8 1.34
miR-144-5p 32.4 2.55
miR-182-5p 32.2 1.11
miR-30d-3p 31.3 1.22
miR-520c-3p 32.1 1.70
miR-550a-5p 32.1 0.29
miR-628-3p 30.5 0.70
miR-944 32.9 0.93
miR-99a-3p 31.1 1.21
miR-942 31.1 0.85
RNU48 32.1 1.03
MiRNAs were considered as expressed only by patients or controls when at
least 3 samples out of 5 have Ct > 35 or show no expression
Gai et al. BMC Cancer  (2018) 18:439 Page 6 of 11
for each miRNA, the number of predicted target genes
in each pathway and the respective p value.
Discussion
The use of saliva as a diagnostic biofluid has been widely
recognized, and it has many advantages over other
specimens like blood, exfoliated cells and urine [26, 27].
Salivary biomarkers have the potential to serve as non-
invasive, widely accessible screening tools. In fact, the
collection is inexpensive and can be easily performed.
Identifying the proper salivary biomarker profile could
contribute to the current screening method of oral
cancer, which is limited to physical exam and biopsy of
suspicious lesions [26].
Several works describe the possibility to detect RNA
biomarkers of numerous diseases in saliva [26–28] and,
more specifically, miRNAs associated with oral cancer
[26–31]. Evidence demonstrates that it is possible to
isolate EV-associated RNA from saliva and oral samples
[28, 32, 33]. However, to date, miRNA expression
analysis in EVs from OSCC have never been reported.
In this work, according to previous evidence [17, 32–35],
we successfully isolated EVs from saliva. A previous study
[17] showed that most of the salivary RNA was associated
with EVs. Through Bioanalyzer RNA profiles, we observed
that EVs were enriched with RNAs ranging from 20 to 200
nucleotides whereas ribosomal RNAs were nearly absent.
Our results are in accordance with other published data of
EV RNA cargo [33, 36, 37]. Molecular analysis of miRNAs
revealed an up-regulation of miR-412-3p, miR-512-3p,
miR-27a-3p, miR-373-3p, miR-494-3p in salivary EVs from
OSCC patients. Furthermore, we found that miR-302b-3p
and miR-517b-3p were expressed specifically only in sam-
ples from the OSCC group. KEGG pathway enrichment
analysis based on predicted miRNA targets provides specu-
lative information of miRNA functions. Eight pathways
showed a statistically significant enrichment with each
pathway predicted to involve two or more miRNAs. For in-
stance, miR-512-3p and miR-27a-3p could target respect-
ively 7 and 20 genes involved in the ErbB signaling
pathway. The pathway is known to promote cell prolifera-
tion and survival in several solid tumors [38] and has been
shown to be activated in OSCC as well [39–41]. MiR-512-
3p, miR-27a-3p, and miR-302b-3p could target respectively
14, 30, and 14 genes regulating proteoglycan in cancer
pathways. Evidence has shown that CD44, which can be
targeted by both miR-512-3p and miR-302b-3p, and the
downstream pathway promote cell invasion and migration
upon c-Fos stimulation in OSCC [42]. Increased CD44 ex-
pression has been associated with ERK1/2 phosphorylation,
Fig. 2 miRNA relative expression detected by qRT-PCR in salivary EV samples from OSCC patients compared to normal subjects. (a) Expression
levels of miRNAs that were significantly up-regulated in patients. (b) Expression levels of miRNAs that were exclusively expressed by OSCC
patients. The bars represent mean relative expression (2^-ΔΔCt) of control and patient groups ± SEM, p value (two-sided Mann-Whitney test) are
reported. ROC curve describing predictive potency of the up-regulated miRNAs as a diagnostic test. The curves represent specificity versus
sensitivity of miR-512-3p (c), miR-412-3p (d). Data are derived from miRNAs’ expression levels (RQ) of OSCC patients and controls. The big gray
dots indicate the optimal threshold value of sensitivity and specificity determined by the maximum Youden’s index (sensitivity+specificity-1)
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and increased tumor aggressiveness [43]. Moreover, high
CD44 levels have been described as a characteristic feature
of cancer stem-like cells in OSCC [44]. In addition, miR-
512-3p, miR-412-3p, miR-27a-3p, and miR-302b-3p could
target several genes of the TGFβ signaling pathway, includ-
ing TGFβR2 gene. Interestingly, it has been previously re-
ported that TGFβR2 is commonly reduced in oral
epithelium and stroma in OSCC patients [45]. In line with
cancer stem like cells, 46 genes involved in signaling path-
ways regulating pluripotency of stem cells can also be tar-
geted by miR-512-3p, miR-27a-3p, miR-494-3p, miR-517b-
3p, and miR-412-3p. The overexpression of Bmi1, which
can be targeted by miR-494 and miR-27a-3p, has been
shown to promote formation, growth, migration, and me-
tastasis in a subpopulation of tumor cells of the HNSCC
[46]. Basing on these observations, we speculate that the
increase of miRNA that target genes involved in tumor
progression in salivary EVs might represent a defenses
mechanism of tumor cells to eliminate anti-tumor miR-
NAs. However, due to the speculative nature of this ana-
lysis, the relation between miRNAs and target genes and
pathways should be further proven experimentally.
To better evaluate the discrimination power of the up-
regulated miRNAs as OSCC biomarkers, we constructed
ROC curves. MiR-512-3p and miR-412-3p resulted to be
either sensitive and specific, as shown by high AUC
values (0.847 and 0.871 respectively, with p values < 0.
02) and maximum Youden’s Index. This indicates that
the two miRNAs are good predictors and can be sug-
gested as new candidate biomarkers for OSCC, which
can be evaluated through further studies on a larger
population. On the other hand, the up-regulation of
miR-27a-3p and miR-494-3p can be used as indicators,
but are not sufficient as diagnostic biomarkers. Never-
theless, the involvement of miR-494-3p and miR-27a-3p
in OSCC is supported by the literature. MiR-494 has
been previously isolated from blood of OSCC patients
and proposed as a biomarker [47]. MiR-27a-3p is in-
volved in the progression of OSCC by targeting YAP1
and therefore inhibiting epithelial to mesenchymal tran-
sition processes [48]. Furthermore, miR-27a-3p can also
target MCPH1, which acts as an onco-suppressor gene
[49]. It has also been proposed that high levels of miR-
27a increase heat sensitivity in OSCC cells, enhancing
hyperthermia-induced-cell death [50]. Moreover, miR-
27a-3p seems to play a role in progression and metastasis
of nasopharyngeal carcinoma [51], gastric cancer [52],
esophageal cancer [53], and has been proposed as an EV-
associated biomarker for colorectal cancer [54]. No
evidence has been reported confirming the involvement of
Fig. 3 KEGG pathway enrichment analysis for up-regulated miRNAs (miR-512-3p, miR-412-3p, miR-27a-3p, miR-494-3p) or miRNAs only expressed
in salivary EV from OSCC patients (miR-302b-3p, miR-517b-3p). (a) The graph shows significantly enriched biological pathways labeled with their
respective p values. X axis shows the number of miRNAs involved in each pathway. (b) The graph shows the number of target genes for each
enriched pathway. (c) The bars represent the number of target genes for each miRNA in each pathway and the respective p value. The legend
(lower-right) shows the color assigned to each pathway and is valid for all the figures (a-c). The p value was calculated with FDR correction and
threshold was set as 0.05
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miR-412-3p, miR-512-3p, miR-302b-3p, and miR-517b-3p
in OSCC, thus our work provides new insights about the
dysregulation of miRNAs in the tumor environment. It is
worth mentioning that miR-512-3p has been reported to
be up-regulated in metastatic prostate cancer [55], and
conversely shown anti-tumor activity in non-small cell
lung cancer [56] and hepatocellular carcinoma [57].
On the other hand, our molecular analysis revealed
the expression, although not statistically significant, of
several miRNAs that have been reported in the literature
as up-regulated in whole saliva or plasma of OSCC
patients and have been proposed as biomarkers. For
example, we observed the expression of both miR-31-5p
and miR-31-3p in OSCC patients, however the levels
were comparable with controls (Additional file 4:
Table S2). Several studies have reported that miR-31
is overexpressed and/or involved in OSCC [58–63].
MiR-184, expressed in OSCC patients and controls,
has been reported to have a good diagnostic value
[30]. MiR-708 is up-regulated in progressing oral pre-
malignant lesions [29] and was increased but without
any statistically significant up-regulation in our group
of patients (Additional file 4: Table S2). The discrep-
ancies among the miRNAs up-regulated in our study
and in other studies in the literature may be due to
the relatively small number of recruited patients and
controls and to the different geographical origin of
the group of cases enrolled in each study. Moreover,
most of the studies detected miRNAs in whole saliva
[18, 20, 29, 30] or plasma [58], instead of salivary
EVs. This may lead to different results since miRNAs
can be differentially represented in whole saliva and
salivary EVs, as it has been previously described for
total plasma or plasma-derived EVs [64, 65].
Conclusions
In this work, we demonstrated the possibility to use
salivary EVs as a non-invasive source of miRNAs for
OSCC diagnosis and we identified two miRNAs (miR-
412-3p and miR-512-3p) overexpressed in OSCC pa-
tients and two miRNAs (miR-302b-3p and miR-517b-
3p) selectively enriched in EVs from OSCC patients.
These four miRNAs have the potential to be used as
biomarkers.
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